Si-Bone Inc (SIBN) Peer Comparison

$19.21

$0.01 (0.05%)

As on 28-Aug-2026 16:00EDT

Market cap

$895 Mln

Revenue (TTM)

$214 Mln

P/E Ratio

--

P/B Ratio

4.9

Div. Yield

0 %

Edit

	Si-Bone Inc (SIBN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	895	12,753	10,906	10,222	9,762
Revenue ($ Mln)	214	1,505	613	785	2,589
Net Profit ($ Mln)	-14.64	160.59	-188.05	41.54	222.40
Net Margin (%)	-6.85	10.67	-30.68	5.29	8.59
RoE (%)	-8.13	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.57	44.47
Price-To-Book	4.91	8.41	16.38	4.84	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Si-Bone Inc (SIBN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	213.60	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	43.74	483.98	127.96	384.30	1,245.50
Gross Profit	159.88	942.44	393.22	347.62	1,343.60
Operating Expenses	187.61	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-17.75	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-14.64	203.83	-192.83	52.15	350.40
Provision for Tax	0.00	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-14.64	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Si-Bone Inc (SIBN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	182.35	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	42.37	210.18	135.71	705.49	2,116.80
Current Liabilities	24.04	233.78	102.33	132.66	961.30
Total Liabilities	238.56	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Si-Bone Inc (SIBN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	28.85	630.60	404.74	1,749.63	7,231.50
Current Assets	219.91	1,344.12	515.78	1,200.55	3,020.50
Total Assets	238.56	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	7.17	212.71	102.84	690.94	1,203.70
Net Current Assets	195.87	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Si-Bone Inc (SIBN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	-0.68	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	4.16	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	3.38	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Si-Bone Inc (SIBN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-9.87	11.76	-22.53	1.79	8.98
ROE (%)	-8.13	10.86	-28.10	1.97	3.04
ROA (%)	-5.54	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-6.30	13.63	-30.58	9.87	-5.99
Net Margin (%)	-6.85	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Si-Bone Inc (SIBN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	15.30	17.55	41.55	16.49	1.37
EBIT Growth (%)	35.15	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	38.41	8.72	-102.66	400.42	-30.32
EPS Growth (%)	40.56	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	3.57	17.33	-12.65	2.16	2.19

Valuation Ratios

	Si-Bone Inc (SIBN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-45.38	68.93	-34.59	189.42	--
Price / Book Value	4.83	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-65.22	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Si-Bone Inc (SIBN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.20	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.00	0.01	0.00	0.01	0.06
Current Ratio	9.15	5.75	5.04	9.05	3.14
Quick Ratio	7.55	3.86	4.46	7.64	2.33
Interest Coverage	-4.88	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Si-Bone Inc (SIBN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	14.60	12.65	22.67	20.09	17.06
Asset Turnover	0.81	0.74	0.59	0.26	0.24
Receivable days	52.15	46.54	60.95	72.41	65.39
Inventory Days	271.27	331.92	193.84	146.53	221.09
Payable days	49.47	26.16	60.19	29.05	37.02
Cash Conversion Cycle	273.95	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly